A consortium led by Cobra  Biomanufacturing (Keele, UK, 

)  has been awarded a £1.1m grant from the UK Department of Trade and Industry to  evaluate the application of Cobra’s proprietary ORT-VAC vaccine technology. The  consortium comprises researchers from the University of Cambridge and the Royal  Holloway, University of London, under the direction of Professor Nigel Slater  and Professor Simon Cutting. Cobra’s proprietary ORT-VAC oral vaccine delivery  system exploits the use of innocuous bacteria to deliver vaccines orally.  Avoiding the need for needles in vaccination increases the ease of vaccine  distribution and administration and simplifies production technology. ORT-VAC  is therefore, ideally suited for the development of vaccines for developing  countries and applications in the animal health sector. The funds awarded will  be largely used to support preclinical experimentation in Cobra’s  collaborators’ laboratories.


News

A consortium led by Cobra Biomanufacturing (Keele, UK, www.cobrabio.com) has been awarded a £1.1m grant from the UK Department of Trade and Industry to evaluate the application of Cobra’s proprietary ORT-VAC vaccine technology.